The adult asthmatic

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Asthma in the adult patient is a complex clinical syndrome. Multiple patient phenotypes and subphenotypes exist that contribute to disease heterogeneity. Whether adult asthma begins in utero, develops in childhood, or manifests for the first time in adulthood is not completely understood, nor are the mechanisms fully delineated. In this chapter, we update definitions that apply to this group, emphasize epidemiologic factors and pathogenic mechanisms, diagnosis, therapeutic options, and controversies regarding drug safety. Finally, we provide a brief discussion of biomarker technologies and novel therapies with the potential to impact adult-onset asthma outcomes.

Original languageEnglish (US)
Pages (from-to)138-155
Number of pages18
JournalClinical Reviews in Allergy and Immunology
Volume43
Issue number1-2
DOIs
StatePublished - Aug 2012

Fingerprint

Asthma
Epidemiologic Factors
Biomarkers
Technology
Phenotype
Safety
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adult-onset asthma
  • Asthma cluster(s)
  • Controller medication
  • COPD
  • Drug safety
  • Guidelines
  • Heterogenous
  • Investigational therapies
  • Late-onset asthma
  • New paradigm
  • Novel treatments
  • Patient compliance
  • Phenotype
  • Severe asthma
  • Statin
  • Step-down therapy
  • Step-up therapy
  • Subphenotype

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

The adult asthmatic. / Zeki, Amir; Kenyon, Nicholas; Yoneda, Ken Y; Louie, Samuel.

In: Clinical Reviews in Allergy and Immunology, Vol. 43, No. 1-2, 08.2012, p. 138-155.

Research output: Contribution to journalArticle

@article{760fad78d26741b194bbc44a29e69e90,
title = "The adult asthmatic",
abstract = "Asthma in the adult patient is a complex clinical syndrome. Multiple patient phenotypes and subphenotypes exist that contribute to disease heterogeneity. Whether adult asthma begins in utero, develops in childhood, or manifests for the first time in adulthood is not completely understood, nor are the mechanisms fully delineated. In this chapter, we update definitions that apply to this group, emphasize epidemiologic factors and pathogenic mechanisms, diagnosis, therapeutic options, and controversies regarding drug safety. Finally, we provide a brief discussion of biomarker technologies and novel therapies with the potential to impact adult-onset asthma outcomes.",
keywords = "Adult-onset asthma, Asthma cluster(s), Controller medication, COPD, Drug safety, Guidelines, Heterogenous, Investigational therapies, Late-onset asthma, New paradigm, Novel treatments, Patient compliance, Phenotype, Severe asthma, Statin, Step-down therapy, Step-up therapy, Subphenotype",
author = "Amir Zeki and Nicholas Kenyon and Yoneda, {Ken Y} and Samuel Louie",
year = "2012",
month = "8",
doi = "10.1007/s12016-011-8260-4",
language = "English (US)",
volume = "43",
pages = "138--155",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "1-2",

}

TY - JOUR

T1 - The adult asthmatic

AU - Zeki, Amir

AU - Kenyon, Nicholas

AU - Yoneda, Ken Y

AU - Louie, Samuel

PY - 2012/8

Y1 - 2012/8

N2 - Asthma in the adult patient is a complex clinical syndrome. Multiple patient phenotypes and subphenotypes exist that contribute to disease heterogeneity. Whether adult asthma begins in utero, develops in childhood, or manifests for the first time in adulthood is not completely understood, nor are the mechanisms fully delineated. In this chapter, we update definitions that apply to this group, emphasize epidemiologic factors and pathogenic mechanisms, diagnosis, therapeutic options, and controversies regarding drug safety. Finally, we provide a brief discussion of biomarker technologies and novel therapies with the potential to impact adult-onset asthma outcomes.

AB - Asthma in the adult patient is a complex clinical syndrome. Multiple patient phenotypes and subphenotypes exist that contribute to disease heterogeneity. Whether adult asthma begins in utero, develops in childhood, or manifests for the first time in adulthood is not completely understood, nor are the mechanisms fully delineated. In this chapter, we update definitions that apply to this group, emphasize epidemiologic factors and pathogenic mechanisms, diagnosis, therapeutic options, and controversies regarding drug safety. Finally, we provide a brief discussion of biomarker technologies and novel therapies with the potential to impact adult-onset asthma outcomes.

KW - Adult-onset asthma

KW - Asthma cluster(s)

KW - Controller medication

KW - COPD

KW - Drug safety

KW - Guidelines

KW - Heterogenous

KW - Investigational therapies

KW - Late-onset asthma

KW - New paradigm

KW - Novel treatments

KW - Patient compliance

KW - Phenotype

KW - Severe asthma

KW - Statin

KW - Step-down therapy

KW - Step-up therapy

KW - Subphenotype

UR - http://www.scopus.com/inward/record.url?scp=84867530805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867530805&partnerID=8YFLogxK

U2 - 10.1007/s12016-011-8260-4

DO - 10.1007/s12016-011-8260-4

M3 - Article

C2 - 21424682

AN - SCOPUS:84867530805

VL - 43

SP - 138

EP - 155

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 1-2

ER -